Rivaroxaban – an effective drug for multiple indications and in diverse patient groups Review article
Article Sidebar
Published:
Mar 31, 2025
Keywords:
anticoagulation, DOAC, rivaroxaban, atrial fibrillation
Main Article Content
Abstract
Rivaroxaban, a direct oral anticoagulant, is used for thromboembolic prevention and treatment. It is the only direct oral anticoagulant recommended for dual therapy in chronic coronary syndrome, peripheral artery disease, and post-acute coronary syndrome. Its pharmacokinetics and safety profile make it suitable for elderly patients, those with chronic kidney disease, and low body weight. In contrast, a once-daily dosage makes it suitable for young patients. The article discusses its use in atrial fibrillation, post-stroke, diabetes, and secondary thrombosis prevention.
Article Details
How to Cite
Skwarek, A., & Ozierański, K. (2025). Rivaroxaban – an effective drug for multiple indications and in diverse patient groups. Medycyna Faktow (J EBM), 18(1(66), 72-76. https://doi.org/10.24292/01.MF.0125.11
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Steffel J, Collins R, Antz M et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021; 23(10): 1612-76.
2. Halperin JL, Hankey GJ, Wojdyla DM et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014; 130(2): 138-46.
3. Prins MH, Lensing AW, Bauersachs R et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11(1): 21.
4. Burness CB, Perry CM. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism. Drugs. 2014; 74(2): 243-62.
5. Weitz JI, Lensing AWA, Prins MH et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017; 376(13): 1211-22.
6. Yeh Y-C, Wang R, Marston XL et al. Improved adherence to anticoagulant therapy with once-daily regimen: a real-world study in patients with atrial fibrillation in Germany. Eur Heart J. 2020; 41(suppl. 2): ehaa946.0455.
7. McHorney CA, Ashton V, Laliberté F et al. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2017; 23(9): 980-8.
8. Moore KT, Krook MA, Vaidyanathan S et al. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. Clin Pharmacol Drug Dev. 2014; 3(4): 321-7.
9. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012; 366(1): 9-19.
2. Halperin JL, Hankey GJ, Wojdyla DM et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014; 130(2): 138-46.
3. Prins MH, Lensing AW, Bauersachs R et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11(1): 21.
4. Burness CB, Perry CM. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism. Drugs. 2014; 74(2): 243-62.
5. Weitz JI, Lensing AWA, Prins MH et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017; 376(13): 1211-22.
6. Yeh Y-C, Wang R, Marston XL et al. Improved adherence to anticoagulant therapy with once-daily regimen: a real-world study in patients with atrial fibrillation in Germany. Eur Heart J. 2020; 41(suppl. 2): ehaa946.0455.
7. McHorney CA, Ashton V, Laliberté F et al. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2017; 23(9): 980-8.
8. Moore KT, Krook MA, Vaidyanathan S et al. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. Clin Pharmacol Drug Dev. 2014; 3(4): 321-7.
9. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012; 366(1): 9-19.